Literature DB >> 9923652

New collagenolytic enzymes/cascade identified at the pannus-hard tissue junction in rheumatoid arthritis: destruction from above.

Y T Konttinen1, A Ceponis, M Takagi, M Ainola, T Sorsa, M Sutinen, T Salo, J Ma, S Santavirta, M Seiki.   

Abstract

Our aim was to investigate the collagenolytic potential and localization of matrix metalloproteinase-2 (MMP-2) in relation to its regulatory proteins membrane type MT1-MMP and tissue inhibitor of metalloproteinases-2 (TIMP-2) in rheumatoid arthritis (RA). For this purpose, we have used purification of MMP-2, MMP-8, MMP-9 and interstitial type I, II and III collagens; SDS-PAGE/densitometric collagenase activity assay; zymography; Western blotting; reverse transcriptase polymerase chain reaction; in situ hybridization; and immunofluorescence, ABC, ABC-APAAP double immunostainings. MMP-2 degraded human type II collagen almost as effectively as MMP-8, whereas MMP-9 did not cleave type II collagen. In synovial tissue, MT1-MMP, TIMP-2 and MMP-2 were found in synovial lining in fibroblast- and macrophage-like cells, in stromal cells and in vascular endothelium. MT1-MMP, TIMP-2 and MMP-2 were strongly expressed in the pannocytes of the invasive pannus at the interface, but staining was weak and/or there were few positive cells both "above" and "below" the soft-to-hard tissue (cartilage and/or bone) interface. Rheumatoid synovial tissue extract contained proteolytically active 62/59 kDa MMP-2 and 43 kDa MT1-MMP, but no free TIMP-2. These results indicate that components of the ternary MT1-MMP/TIMP-2/MMP-2 complex are coexpressed in the normal synovial lining and in its pathological extension on the hyaline articular cartilage. MMP-2 may participate in the remodeling of the normal lining and also seems to be localized/focalized to pannocytes at a site critical for tissue destruction in arthritis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9923652     DOI: 10.1016/s0945-053x(98)90110-x

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  22 in total

Review 1.  MMPs and rheumatoid synovial fibroblasts: Siamese twins in joint destruction?

Authors:  U Müller-Ladner; S Gay
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 2.  Matrix metalloproteinase collagenolysis in health and disease.

Authors:  Sabrina Amar; Lyndsay Smith; Gregg B Fields
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2017-04-26       Impact factor: 4.739

3.  Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis.

Authors:  Y T Konttinen; M Ainola; H Valleala; J Ma; H Ida; J Mandelin; R W Kinne; S Santavirta; T Sorsa; C López-Otín; M Takagi
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

4.  Alpinia galanga extracts downregulate interleukin-1β-induced matrix metalloproteinases expression in human synovial fibroblasts.

Authors:  Peraphan Pothacharoen; Kanyamas Choocheep; Thanyaluck Phitak; Wilart Pompimon; Prachya Kongtawelert
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-12-04       Impact factor: 2.416

5.  Increased levels of the 14-3-3 η and γ proteins in the synovial fluid of dogs with unilateral cranial cruciate ligament rupture.

Authors:  Kamran Sardari; Claudia Chavez-Muñoz; Ruhangiz T Kilani; Terri Schiller; Aziz Ghahary
Journal:  Can J Vet Res       Date:  2011-10       Impact factor: 1.310

6.  Characterisation of the cell type-specificity of collagenase 3 mRNA expression in comparison with membrane type 1 matrix metalloproteinase and gelatinase A in the synovial membrane in rheumatoid arthritis.

Authors:  P K Petrow; D Wernicke; C Schulze Westhoff; K M Hummel; R Bräuer; J Kriegsmann; E Gromnica-Ihle; R E Gay; S Gay
Journal:  Ann Rheum Dis       Date:  2002-05       Impact factor: 19.103

Review 7.  The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders.

Authors:  S Elliott; T Cawston
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

8.  Polyoxypregnane glycoside from Dregea volubilis extract inhibits IL-1β-induced expression of matrix metalloproteinase via activation of NF-κB in human chondrocytes.

Authors:  Akanit Itthiarbha; Thanyaluck Phitak; Saksri Sanyacharernkul; Peraphan Pothacharoen; Wilart Pompimon; Prachya Kongtawelert
Journal:  In Vitro Cell Dev Biol Anim       Date:  2011-12-18       Impact factor: 2.416

9.  The inactive 44-kDa processed form of membrane type 1 matrix metalloproteinase (MT1-MMP) enhances proteolytic activity via regulation of endocytosis of active MT1-MMP.

Authors:  Jin-Ah Cho; Pamela Osenkowski; Huiren Zhao; Seaho Kim; Marta Toth; Kristina Cole; Amro Aboukameel; Allen Saliganan; Lucia Schuger; R Daniel Bonfil; Rafael Fridman
Journal:  J Biol Chem       Date:  2008-04-15       Impact factor: 5.157

10.  Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis.

Authors:  Mary-Clare Miller; Hugh B Manning; Abhilash Jain; Linda Troeberg; Jayesh Dudhia; David Essex; Ann Sandison; Motoharu Seiki; Jagdeep Nanchahal; Hideaki Nagase; Yoshifumi Itoh
Journal:  Arthritis Rheum       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.